Should I buy or sell Rallybio stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLYB shares. View RLYB analyst ratings or view top-rated stocks .

What is Rallybio's stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they anticipate the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 593.2% from the stock's current price. View analysts price targets for RLYB or view top-rated stocks among Wall Street analysts .

How have RLYB shares performed in 2024?

Rallybio's stock was trading at $2.39 on January 1st, 2024. Since then, RLYB shares have decreased by 26.4% and is now trading at $1.76. View the best growth stocks for 2024 here .

When is Rallybio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RLYB earnings forecast .

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) posted its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.06.

When did Rallybio IPO?

Rallybio (RLYB) raised $80 million in an IPO on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RLYB

Rallybio (RLYB) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free RLYB Stock Alerts

$1.76

+0.09 (+5.39%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.65
▼
$1.82
50-Day Range: $1.47
▼
$2.98
52-Week Range: $1.23
▼
$9.14

Volume: 317,943 shs
Average Volume: 4.54 million shs
Market Capitalization: $66.55 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.20

Get Rallybio alerts:

Rallybio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 593.2% Upside
$12.20 Price Target
Short Interest: Bearish
7.60% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.52) to ($1.34) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.38 out of 5 stars

Medical Sector

487th out of 911 stocks

Pharmaceutical Preparations Industry

220th out of 419 stocks

3.4

Analyst's Opinion

Consensus Rating
Rallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Rallybio has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.60% of the float of Rallybio has been sold short.
Short Interest Ratio / Days to Cover
Rallybio has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Rallybio has recently increased by 2.34%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Rallybio does not currently pay a dividend.
Dividend Growth
Rallybio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RLYB.

3.7

News and Social Media Coverage

News Sentiment
Rallybio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Rallybio this week, compared to 1 article on an average week.
Search Interest
7 people have searched for RLYB on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
6 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rallybio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.80% of the stock of Rallybio is held by insiders.
Percentage Held by Institutions
90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Rallybio are expected to grow in the coming year, from ($1.52) to ($1.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rallybio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rallybio is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rallybio has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Rallybio Stock (NASDAQ:RLYB)

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

RLYB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RLYB Stock News Headlines

April 20, 2024 | americanbankingnews.com

Rallybio (NASDAQ:RLYB) Rating Reiterated by JMP Securities

April 18, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT Treatment

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 17, 2024 | msn.com

Rallybio (RLYB) Price Target Decreased by 16.00% to 12.85

April 17, 2024 | businesswire.com

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

April 15, 2024 | americanbankingnews.com

Q1 2024 Earnings Estimate for Rallybio Co. (NASDAQ:RLYB) Issued By Wedbush

April 14, 2024 | finance.yahoo.com

Cozad New Venture Challenge Demo Day awards student start-ups with funding

April 13, 2024 | americanbankingnews.com

Rallybio (NASDAQ:RLYB) Price Target Cut to $11.00

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

April 12, 2024 | investing.com

Rallybio partners with Johnson & Johnson on FNAIT treatment

April 11, 2024 | msn.com

Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher

April 11, 2024 | proactiveinvestors.com

Rallybio partners with J&J to advance therapies targeting rare fetal disease

April 11, 2024 | msn.com

Rallybio shares gain on investment from J&J for rare fetal condition treatment

April 11, 2024 | investorplace.com

Why Is Rallybio (RLYB) Stock Up 93% Today?

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program Progress

April 10, 2024 | businesswire.com

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

April 1, 2024 | finance.yahoo.com

Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market Potential

March 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial Stability

March 12, 2024 | benzinga.com

Rallybio: Q4 Earnings Insights

March 12, 2024 | finance.yahoo.com

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

February 26, 2024 | businesswire.com

Rallybio to Present at the TD Cowen 44th Annual Health Care Conference

February 7, 2024 | msn.com

Jefferies cuts Rallybio to hold, cites lack of near-term catalysts

February 7, 2024 | msn.com

Rallybio Announces Workforce Reduction and Restructuring Costs

February 7, 2024 | markets.businessinsider.com

Rallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy Rating

February 6, 2024 | markets.businessinsider.com

Rallybio Announces Portfolio Prioritization Plan; To Reduce Workforce By 45%

February 6, 2024 | msn.com

Madrigal Pharmaceuticals, Cerus among healthcare movers

See More Headlines

Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/12/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RLYB
CUSIP: N/A
CIK: 1739410
Web: www.rallybio.com
Phone: 203-59-3820
Fax: N/A
Employees: 43
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.20
High Stock Price Target: $18.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +593.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,560,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -56.90%
Return on Assets: -53.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.39
Quick Ratio: 12.39

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.81 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 37,810,000
Free Float: 35,619,000
Market Cap: $66.55 million
Optionable: Not Optionable
Beta: -1.64

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Martin W. MacKay Ph.D. (Age 68)
Co-Founder & Executive Chairman
Comp: $723.35k
Dr. Stephen Uden M.B (Age 66)
M.D., Co-Founder, President, CEO & Director
Comp: $723.35k
Mr. Jonathan I. Lieber M.B.A. (Age 54)
CFO & Treasurer
Comp: $667.13k

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RLYB Stock Analysis - Frequently Asked Questions

Should I buy or sell Rallybio stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RLYB shares.
View RLYB analyst ratings or view top-rated stocks.
What is Rallybio's stock price target for 2024?: 6 Wall Street analysts have issued 1 year price objectives for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they anticipate the company's share price to reach $12.20 in the next twelve months. This suggests a possible upside of 593.2% from the stock's current price.
View analysts price targets for RLYB or view top-rated stocks among Wall Street analysts.
How have RLYB shares performed in 2024?: Rallybio's stock was trading at $2.39 on January 1st, 2024. Since then, RLYB shares have decreased by 26.4% and is now trading at $1.76.
View the best growth stocks for 2024 here.
When is Rallybio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RLYB earnings forecast.

How were Rallybio's earnings last quarter?: Rallybio Co. (NASDAQ:RLYB) posted its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.06.
When did Rallybio IPO?: Rallybio (RLYB) raised $80 million in an IPO on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share.
How do I buy shares of Rallybio?: Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLYB) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rallybio (RLYB) Stock Price, News & Analysis

Rallybio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Rallybio Stock (NASDAQ:RLYB)

RLYB Stock Price History

RLYB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

RLYB Stock Analysis - Frequently Asked Questions

Overall MarketRank^™